Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CGAS | Q8N884 | 5/20 | 0.42 |
| ▸ | CFTR | P13569 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461873 | 1.00 | MEN1 (0.57) | MEN1POLBKMT2ANLRP3ALOX5 | |
| SCHEMBL3277109 | 0.77 | AMY1A (0.61) | MEN1POLBKMT2ANLRP3ALOX5 | |
| SCHEMBL3277107 | 0.77 | AMY1A (0.61) | MEN1POLBKMT2ANLRP3ALOX5 | |
| SCHEMBL5787549 | 0.73 | NLRP3 (0.64) | MEN1POLBKMT2ANLRP3ALOX5 | |
| SCHEMBL5787551 | 0.73 | NLRP3 (0.64) | MEN1POLBKMT2ANLRP3ALOX5 | |
| SCHEMBL5462391 | 0.71 | NLRP3 (0.62) | NLRP3PIM1CFTRPTPN1PPARG | |
| SCHEMBL5462396 | 0.71 | NLRP3 (0.62) | NLRP3PIM1CFTRPTPN1PPARG | |
| SCHEMBL8689993 | 0.71 | NLRP3 (0.49) | NLRP3PIM1CGASPTPN1PPARG | |
| SCHEMBL5460280 | 0.70 | MEN1 (0.60) | MEN1POLBKMT2ANLRP3ALOX5 | |
| SCHEMBL5460282 | 0.70 | MEN1 (0.60) | MEN1POLBKMT2ANLRP3ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | MEN1 2892/4885POLB 3236/4885KMT2A 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.